Search
Shenji Changhua's Gene Therapy SNUG01 for ALS Receives FDA Orphan Drug Designation
1 day ago /
Read about 0 minute
Author：小编
Shenji Changhua's pioneering gene therapy, SNUG01, specifically targeting the TRIM72 gene, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of Amyotrophic Lateral Sclerosis (ALS). This esteemed designation will expedite the approval process for SNUG01 and provide it with various benefits, such as tax credits for clinical research expenditures, exemption from biologics license application fees, and an exclusive seven-year market period.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
